Last $7.54 USD
Change Today +0.14 / 1.89%
Volume 2.2M
ARAY On Other Exchanges
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

accuray inc (ARAY) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/3/14 - $10.85
52 Week Low
10/30/14 - $5.99
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ACCURAY INC (ARAY)

accuray inc (ARAY) Related Businessweek News

No Related Businessweek News Found

accuray inc (ARAY) Details

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. Accuray Incorporated markets its products in the United States directly, as well as through a sales agent and group purchasing organizations; and directly and through distributors in Europe, Japan and rest of Asia, South America, and internationally to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.

1,026 Employees
Last Reported Date: 08/29/14
Founded in 1990

accuray inc (ARAY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $637.5K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $293.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $368.1K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $330.6K
Total Annual Compensation: $154.7K
Compensation as of Fiscal Year 2014.

accuray inc (ARAY) Key Developments

Accuray Incorporated Announces Encouraging Results from Neurological Diseases Studies

Accuray Incorporated has announced the results from studies that support the benefits of the CyberKnife Robotic Radiosurgery System for the treatment of neurological diseases such as meningiomas, acoustic neuromas, trigeminal neuralgia, and spinal tumors. Dr. Alfredo Conti, neurosurgeon at the University Hospital of Messina in Italy is using the CyberKnife System to treat perioptic meningiomas. The flexibility of the CyberKnife System enabled by its unique architecture allows tumor control while preserving vision. The results he presented in a plenary session included a series of 64 patients with perioptic meningiomas treated in 2-5 fractions with CyberKnife schemes between July 2007 - May 2010. The study included two cohorts of patients with different tumor volumes. In one cohort, 25 patients with a small tumor volume were followed for an average of 60 months. In the second cohort, 39 patients with a larger tumor volume were followed for an average of 17 months. No visual deterioration was observed and tumor control was achieved in all cases. These results support the clinical benefits of CyberKnife treatment for perioptic meningiomas, and were achieved the ability to fractionate depending on the tumor volume and its proximity to the optic nerve. This is a real breakthrough because treating large tumors with radiosurgery in a single fraction is very challenging, and often not possible. Furthermore, treating tumors close to the optic nerves or other critical brain structures is sometimes very challenging for neurosurgeons and the CyberKnife System represents a safer and effective treatment option.

Accuray and Lausanne University Hospital Join Forces to Offer Patients Personalized Radiation Therapy Treatments

Accuray Incorporated announced a long-term collaboration with Lausanne University Hospital, Switzerland covering the CyberKnife® and TomoTherapy® Systems. The alliance is based on a mutual commitment to ongoing research in radiation oncology and the development of innovative treatments that improve the quality of life for cancer patients. At Lausanne University Hospital, patients will now have access to the newest CyberKnife and TomoTherapy Systems on the market. Healthcare professionals may also gain exposure to both systems through peer-to-peer training and education at the hospital. In addition, the two respected organizations intend to collaborate on clinical development and ongoing product innovations, benefiting both healthcare professionals and their patients.

Accuray Incorporated Reports Unaudited Consolidated Earnings Results for the First Quarter Ended September 30, 2014; Reaffirms Earnings Guidance for the Full Year of 2015

Accuray Incorporated reported unaudited consolidated earnings results for the first quarter ended September 30, 2014. For the quarter, total net revenue was $82,381,000 against $76,641,000 a year ago. Loss from operations was $15,272,000 against $12,286,000 a year ago. Loss before provision for income taxes was $20,733,000 against $14,746,000 a year ago. Net loss was $21,650,000 or $0.28 per basic and diluted share against $15,533,000 or $0.21 per basic and diluted share a year ago. Adjusted EBITDA loss was $8,494,000 against $3,812,000 a year ago. The company reaffirmed its earnings guidance for the full year of 2015. The company expects total revenue to be in the range of $390 million to $410 million and adjusted EBITDA to be in the range of $18 million to $27 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARAY:US $7.54 USD +0.14

ARAY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Elekta AB kr81.25 SEK +0.25
IsoRay Inc $1.60 USD 0.00
Mitsubishi Heavy Industries Ltd ¥681.90 JPY -3.20
RaySearch Laboratories AB kr51.50 SEK +0.75
Varian Medical Systems Inc $88.04 USD +0.87
View Industry Companies

Industry Analysis


Industry Average

Valuation ARAY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.6x
Price/Book 7.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACCURAY INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at